Endo Products

Endo is a specialty pharmaceutical company focused on developing and commercializing high-value branded and generic therapies. The company maintains a leading position in medical aesthetics, orthopedics, urology, and endocrinology, anchored by its flagship biologic product, Xiaflex. In addition to its branded portfolio, Endo operates a significant generic medicines business through its subsidiary, Par Pharmaceutical, which provides a wide range of complex and difficult-to-manufacture generics. Following a successful financial restructuring in May 2024, the company emerged as Endo, Inc., a private entity owned by its former creditors. Endo continues to leverage its integrated manufacturing and R&D capabilities to deliver life-enhancing treatments to patients across North America and international markets.